396 related articles for article (PubMed ID: 30805659)
1. Clinical implications of cardiovascular outcome trials in type 2 diabetes.
Mellbin LG; Wang A; Rydén L
Herz; 2019 May; 44(3):192-202. PubMed ID: 30805659
[TBL] [Abstract][Full Text] [Related]
2. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects of antidiabetic drugs.
Sørensen AM; Christensen MB
Drugs Today (Barc); 2018 Sep; 54(9):547-559. PubMed ID: 30303495
[TBL] [Abstract][Full Text] [Related]
4. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
Kramer CK; Ye C; Campbell S; Retnakaran R
JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.
Gómez-Huelgas R; Sanz-Cánovas J; Cobos-Palacios L; López-Sampalo A; Pérez-Belmonte LM
Eur J Intern Med; 2022 Feb; 96():26-33. PubMed ID: 34799233
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
7. Risk factor reduction in type 2 diabetes demands a multifactorial approach.
Rydén L; Ferrannini G; Mellbin L
Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):81-91. PubMed ID: 31766912
[TBL] [Abstract][Full Text] [Related]
8. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
[TBL] [Abstract][Full Text] [Related]
9. Glucose-Lowering Medications and Cardiovascular Outcomes.
Shanmugasundaram M; Pineda JRE; Murugapandian S
Curr Cardiol Rep; 2021 Mar; 23(4):24. PubMed ID: 33655453
[TBL] [Abstract][Full Text] [Related]
10. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
Secrest MH; Udell JA; Filion KB
Trends Cardiovasc Med; 2017 Apr; 27(3):194-202. PubMed ID: 28291655
[TBL] [Abstract][Full Text] [Related]
11. Type 2 Diabetes Medication and Cardiovascular Benefits.
Shrestha A; Munankarmi R
S D Med; 2021 Mar; 74(3):132-135. PubMed ID: 34232594
[TBL] [Abstract][Full Text] [Related]
12. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
13. [Evidence-based reduction of cardiovascular risk in patients with diabetes].
Schütt KA
Herz; 2020 Apr; 45(2):118-121. PubMed ID: 31820029
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
Thompson PL; Davis TME
Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
[TBL] [Abstract][Full Text] [Related]
15. New Glucose-Lowering Agents for Diabetic Kidney Disease.
de Vos LC; Hettige TS; Cooper ME
Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
[TBL] [Abstract][Full Text] [Related]
16. Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis.
Hu J; Chen L
Prim Care Diabetes; 2021 Apr; 15(2):227-233. PubMed ID: 32888896
[TBL] [Abstract][Full Text] [Related]
17. Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).
Liakos CI; Papadopoulos DP; Sanidas EA; Markou MI; Hatziagelaki EE; Grassos CA; Velliou ML; Barbetseas JD
Am J Cardiovasc Drugs; 2021 Mar; 21(2):123-137. PubMed ID: 32780214
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular safety of therapies for type 2 diabetes.
Gupta P; White WB
Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
[TBL] [Abstract][Full Text] [Related]
19. Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG.
Rydén L; Shahim B; Mellbin L
Clin Ther; 2016 Jun; 38(6):1279-1287. PubMed ID: 27107734
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
Sharma A; Verma S
Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
